Ah, zee germanz!
"The German team reported that of four patients with metastatic prostate cancer who were assessed for radiologic progression-free survival, two had not progressed at 24 and 18 months of follow-up and the other two had progression at 12 and 15 months. The researchers also found that starting prostate-specific antigen levels were reduced by 100%, 99%, 88%, and 35% for the four individual patients."
The trial is undergoing in the US as well, I have not checked where
It sounds optimistic. Hope it goes well in the US!
thanks for sharing. This is really interesting and hopeful. My husband worked on this diagnostic imaging equipment and he said something like this would be a game changer. I just read him the article posted in urology times. urologytimes.com/view/initi...
Clinical Trial # NCT05413850
Sounds like great opportunity's to survive longer!
One of the exclusions criteria is
16: Previous treatment with any of the following: PSMA targeted radionuclide therapy, Strontium-89, Samarium-153, Rhenium 186, Rhenium-188, Radium-223, hemi-body irradiation.
Lutetium Lu 177 Vipivotide Tetraxetan 
Lutetium 177
Jevtana failed, next Lutetium-177
